Outcome from surgery for vestibular schwannomas in children

References

• Tos M, Stangerup S E, Caye-Thomasen P, Tos T, Thomsen J. What is the real incidence of vestibular schwannoma?. Arch Otolaryngol Head Neck Surg 2004; 130: 216–220
   PubMedGoogle Scholar
• Evans D G, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the north west of England over a 10-year period: Higher incidence than previously thought. Otol Neurotol 2005; 26: 93–97
   PubMed Web of Science ®Google Scholar
• Evans D G, Huson S M, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84: 603–618
   PubMedGoogle Scholar
• Baser M E, Makariou E V, Parry D M. Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 2002; 96: 217–222
   Google Scholar
• Mautner V F, Baser M E, Thakkar S D, Feigen U M, Friedman J M, Kluwe L. Vestibular schwannoma growth in patients with neurofibromatosis type 2: A longitudinal study. J Neurosurg 2002; 96: 223–228
   Google Scholar
• Otsuka G, Saito K, Nagatani T, Yoshida J. Age at symptom onset and long-term survival in patients with neurofibromatosis type 2. J Neurosurg 2003; 99: 480–483
   PubMed Web of Science ®Google Scholar
• Rutherford S A, King A T. Vestibular schwannoma management: What is the ‘best’ option?. Br J Neurosurg 2005; 19: 309–316
   PubMed Web of Science ®Google Scholar
• Evans D G, Birch J M, Ramsden R T, Sharif S, Baser M E. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43: 289–294
   PubMed Web of Science ®Google Scholar
• Freeman S R, Ramsden R T, Saeed S R, Alzoubi F Q, Simo R, Rutherford S A, King A T. Revision surgery for residual or recurrent vestibular schwannoma. Otol Neurotol 2007; 28: 1076–1082
   PubMed Web of Science ®Google Scholar
• Jacob A, Robinson L L, Jr., Bortman J S, Yu L, Dodson E E, Welling D B. Nerve of origin, tumor size, hearing preservation, and facial nerve outcomes in 359 vestibular schwannoma resections at a tertiary care academic center. Laryngoscope 2007; 117: 2087–2092
   PubMed Web of Science ®Google Scholar
• Mohr G, Sade B, Dufour J J, Rappaport J M. Preservation of hearing in patients undergoing microsurgery for vestibular schwannoma: Degree of metal filling. J Neurosurg 2005; 102: 1–5
   PubMed Web of Science ®Google Scholar
• Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): Auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997; 40: 696–705, discussion 705-696
   PubMed Web of Science ®Google Scholar
• Slattery W H, 3rd, Fisher L M, Hitselberger W, Friedman R A, Brackmann D E. Hearing preservation surgery for neurofibromatosis type 2-related vestibular schwannoma in pediatric patients. J Neurosurg 2007; 106: 255–260
   PubMedGoogle Scholar
• Yang J, Grayeli A B, Barylyak R, Elgarem H. Functional outcome of retrosigmoid approach in vestibular schwannoma surgery. Acta Otolaryngol 2008; 128: 881–886
   PubMed Web of Science ®Google Scholar
• Martin T P, Tzifa K, Kowalski C, Holder R L, Walsh R, Irving R M. Conservative versus primary surgical treatment of acoustic neuromas: A comparison of rates of facial nerve and hearing preservation. Clin Otolaryngol 2008; 33: 228–235
   Google Scholar
• Evans D G, Ramsden R T, Gokhale C, Bowers N, Huson S M, Wallace A. Should nf2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?. Clin Genet 2007; 71: 354–358
   Google Scholar
• Baser M E, Kuramoto L, Joe H, Friedman J M, Wallace A J, Gillespie J E, Ramsden R T, Evans D G. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: A population-based study. Am J Hum Genet 2004; 75: 231–239
   PubMed Web of Science ®Google Scholar
• Evans D G, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (nf2): Evidence for more severe disease associated with truncating mutations. J Med Genet 1998; 35: 450–455
   PubMedGoogle Scholar
• Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner V F. Phenotypic variability associated with 14 splice-site mutations in the nf2 gene. Am J Med Genet 1998; 77: 228–233
   Google Scholar
• Ruttledge M H, Andermann A A, Phelan C M, Claudio J O, Han F Y, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi V M, Weksberg R, Kitamura K, Bradburn J M, Hall B D, Propping P, Rouleau G A. Type of mutation in the neurofibromatosis type 2 gene (nf2) frequently determines severity of disease. Am J Hum Genet 1996; 59: 331–342
   PubMed Web of Science ®Google Scholar